Developmental toxicity of ribavirin/IFα combination therapy: Is the label more dangerous than the drugs?
- 29 January 2003
- journal article
- editorial
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 67 (1), 8-12
- https://doi.org/10.1002/bdra.10020
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Male periconceptional ribavirin-interferon alpha-2B exposure with no adverse fetal effectsBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Classification of drugs for teratogenic risk: An anachronistic way of counselingTeratology, 2002
- Birth defect surveillance at the state and local levelTeratology, 1997
- Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancyReproductive Toxicology, 1996
- Normal pregnancy under inadvertent alpha-interferon therapy for chronic hepatitis CJournal of Hepatology, 1996
- Anti-cholesterol agent pregnancy exposure outcomesReproductive Toxicology, 1994
- Interferon‐α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemiaBritish Journal of Haematology, 1992
- The Effects of Ribavirin on Development and Reproduction: A Critical Review of Published and Unpublished Studies in Experimental AnimalsJournal of the American College of Toxicology, 1990
- Teratogenic effects of ribavirin on hamster and rat embryosTeratology, 1978
- Congenital Anomalies Induced in Hamster Embryos with RibavirinScience, 1977